user
menu
letter
Sign InRegister
langEnglisharrow

IL-2 R alpha

IL-2 R alpha

IL-2 R alpha Overview

Molecule Name
Interleukin-2 receptor alpha chain
Synonyms
IL2RA,CD25,p55,IL2-RA,IL-2-RA
Drug Development Progress
Drugs in Clinical Trials16
Approved Drugs3
Highest Development StageApproved
Target Synonym
TAC antigen，p55，IL2-RA，Interleukin-2 receptor subunit alpha，IL-2-RA，IL-2R subunit alpha，IL2RA，Interleukin 2 Receptor Subunit Alpha，Interleukin 2 Receptor， Alpha，IL-2 Receptor Subunit Alpha，Insulin-Dependent Diabetes Mellitus 10，CD25 Antigen，IDDM10，IMD41，TCGFR，CD25，Interleukin-2 Receptor alpha Subunit，IL-2R alpha
Background
Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

IL-2 R alpha Product List

Species
  • Human（4）
  • Cynomolgus（2）
  • Mouse（2）
  • Canine（1）
  • Rat（1）
  • Rhesus macaque（1）
Tag
  • His Tag（6）
  • His Tag & Avi Tag（3）
  • Fc Tag（1）
  • Fc Tag & Avi Tag（1）
Host
  • HEK293（11）
Conjugate
  • Unconjugated（7）
  • Biotin-labeled（4）
Grade
  • RUO（10）
  • PG (pre-GMP)（1）
Low Endotoxin
  • Yes（3）
  • No（8）
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
IL-2 R alpha
HOT
ILA-C52H8
Cynomolgus IL-2 R alpha / CD25 Protein, His Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$310.00

100ug
IL-2 R alpha
HOTAIDD‑Ready
ILA-H52H9
Human IL-2 R alpha / CD25 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLICELL BASE

$375.00

100ug
IL-2 R alpha
HOTAvitagAIDD‑Ready
ILA-H82E6
Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade
Human
HEK293
MALSSDS-PAGE
ELISABLICELL BASE

$360.00

25ug
IL-2 R alpha
HOT
ILA-H5251
Human IL-2 R alpha / CD25 Protein, Fc Tag, low Endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$325.00

100ug
IL-2 R alpha
HOTAIDD‑Ready
ILA-M52H9
Mouse IL-2 R alpha / CD25 Protein, His Tag (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISABLI

$340.00

100ug
IL-2 R alpha
ILA-C52H4
Canine IL-2 R alpha / CD25 Protein, His Tag
Canine
HEK293
SDS-PAGE
ELISA

$310.00

100ug
IL-2 R alpha
AvitagAIDD‑Ready
ILA-C82E4
Biotinylated Cynomolgus IL-2 R alpha / CD25 Protein, His,Avitag™ (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$360.00

25ug
IL-2 R alpha
Avitag
ILA-H82F9
Biotinylated Human IL-2 R alpha / CD25 Protein, Fc,Avitag™ (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISA

$360.00

25ug
IL-2 R alpha
AvitagAIDD‑Ready
ILA-M82E9
Biotinylated Mouse IL-2 R alpha / CD25 Protein, His,Avitag™ (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISASPR

$360.00

25ug
IL-2 R alpha
AIDD‑Ready
ILA-R52H3
Rhesus macaque IL-2 R alpha / CD25 Protein, His Tag (MALS verified)
Rhesus macaque
HEK293
MALSSDS-PAGE
ELISASPR

$310.00

100ug
You Have Viewed 1-10 Of 11 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

Product InquiryRequest Customization
Asset Licensing Opportunity

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
CD25 mAb - 01PCCMonoclonalHumanized MouseSolid TumorSolid tumor
Project Name
CD25 mAb - 01
Project Stage
PCC
Molecule Type
Monoclonal
Molecule Source
Humanized Mouse
Disease Area
Solid Tumor
Indication
Solid tumor
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Basiliximab biobetter (Mabtech/Sorrento)STI-003Phase 3 ClinicalTaizhou Maibo Taike Biotechnology Co Ltd
Autoimmune Diseases
Details
LMB-2LMB-2; LMB-2aPhase 2 ClinicalNational Cancer Institute
Leukemia; Leukemia, Hairy Cell; Leukemia, T-Cell; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Myeloproliferative Disorders; Skin Melanoma; Skin Neoplasms
Details
Nemvaleukin alfaRDB-1419; RDB-1450; ALKS-4230Phase 2 ClinicalAlkermes Plc
Fallopian Tube Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Skin Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
Camidanlumab tesirineADCT-301Phase 2 ClinicalAdc Therapeutics Sa, Genmab A/S
Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Melanoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Ovarian Neoplasms; Pancreatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
90Y-HAT (NCI)Phase 2 ClinicalNational Cancer Institute
Hodgkin Disease; Lymphoma, Non-Hodgkin
Details
Humanized Anti-CD25 Antibody(Institute of Hematology & Blood Diseases Hospital)Phase 2 ClinicalInstitute Of Hematology & Blood Diseases Hospital
Graft vs Host Disease
Details
90Y BasiliximabPhase 2 ClinicalCity Of Hope National Medical Center
Hodgkin Disease; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
PT-101PT-101; MK-6194; PT101Phase 1 ClinicalPandion Therapeutics
Colitis, Ulcerative; Dermatitis, Atopic; Lupus Erythematosus, Systemic; Vitiligo
Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1HuMikβ1-1Phase 1 ClinicalF. Hoffmann-La Roche Ltd, National Institutes Of Health
Celiac Disease; Leukemia; Leukemia, Large Granular Lymphocytic; Leukemia, Lymphoid; Paraparesis, Tropical Spastic
Details
BA-1106TS-1904; BA-1106; RR-102Phase 1 ClinicalShandong Boan Biotechnology Co Ltd
Solid tumours
Details
XmAb-564XmAb-564; XmAb564; XmAb-27564Phase 1 ClinicalXencor Inc
Autoimmune Diseases; Dermatitis, Atopic; Psoriasis
Details
PF-08046032PF-08046032Phase 1 ClinicalPfizer Inc
Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck
Details
IL2 CD25 fusion protein (Bristol-Myers Squibb)Phase 1 ClinicalUniversity Of Miami
Autoimmune Diseases
Details
9MW-39119MW3911; 9MW-3911Phase 1 ClinicalNanjing Nuo Aixin Biotechnology Co Ltd
Neoplasms
Details
In 111-DOTA-BasiliximabPhase 1 ClinicalCity Of Hope National Medical Center
Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
BMS-986326BMS-986326Phase 1 ClinicalBristol-Myers Squibb Company
Dermatitis, Atopic; Lupus Vulgaris
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Daclizumab biosimilar (Shanghai CP Guojian)ApprovedSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd健尼哌Mainland ChinaRejection of renal transplantationnull2011-01-12
Rejection of renal transplantation
Details
DaclizumabR-35; BIIB-019; RO-247375ApprovedAbbvie Inc, Biogen Inc, F. Hoffmann-La Roche LtdZinbryta, ZenapaxUnited StatesRejection of organ transplantationF. Hoffmann-La Roche Ag1997-12-10
Anemia, Aplastic; Anemia, Diamond-Blackfan; Arthritis, Juvenile; Asthma; Behcet Syndrome; Breast Neoplasms; Carcinoma, Ductal; Colitis, Ulcerative; Diabetes Mellitus, Type 1; Gastrointestinal Diseases; Granulomatosis with Polyangiitis; HIV Infections; HTLV-I Infections; Inflammatory Bowel Diseases; Iritis; Leukemia; Leukemia, T-Cell; Lymphoma; Melanoma; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelodysplastic Syndromes; Psoriasis; Radiation Injuries; Red-Cell Aplasia, Pure; Rejection in heart transplantation; Rejection of organ transplantation; Retinal Diseases; Thrombocytopenia; Uveitis; Uveitis, Anterior
Details
BasiliximabCHT-25; chRFT5; CHI-621; SDZ-CHI-621ApprovedNovartis Pharma Ag舒莱, SimulectUnited StatesRejection of organ transplantationNovartis Pharma Ag1998-05-12
Anemia, Aplastic; Colitis, Ulcerative; Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Emphysema; Hemoglobinuria, Paroxysmal; Hodgkin Disease; Keratoplasty rejection; Kidney Failure, Chronic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pulmonary Disease, Chronic Obstructive; Rejection of renal transplantation; Rejection of organ transplantation; Uveitis
Details
Customer Reviews
  • E***n2023-04-08
    Human IL-2 R alpha / CD25 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
    Yeast cells expressing and displaying different IL2 variants were incubated 1h in the presence of CD25 protein with His tag (Human Il-2 R alpha Acrobiosystems #ILA-H52H9) at a final concentration of 4µg/ml. Next, cells were washed and incubated with a mouse Anti-His-PE. The yeast cells were washed and were analyzed using FACS. We observed detectable amounts of fluorescence bound to yeast cells displaying specific IL2 variants confirming that CD25 could bind to certain constructs and providing evidence that certain IL2 variants were correctly folded.
  • 1***22022-08-03
    Mouse IL-2 R alpha / CD25 Protein, His Tag (MALS verified)
    I purchased the company’s mouse-derived CD25 protein for the evaluation of CD25 antibody affinity. It achieved a high sensitivity detection with a small amount! Very satisfied, will come back to purchase more if needed!